Mark Breidenbach


Kite Pharma Inc (KITE) Takes Compelling Step Forward Toward Securing Broad Label in Non-Hodgkin Lymphoma

Yesterday, Kite Pharma Inc (NASDAQ:KITE) impressed at the 2017 American Association of Cancer Research annual meeting, presenting an encouraging full six- month data …

Roth Capital Boosts Price Target for Kite Pharma Inc (KITE) on the Back of Positive Six Month ZUMA-1 Data

Kite Pharma Inc (NASDAQ:KITE) shares are on the run, after the drug maker announced the much-awaited top line results from its Phase 2 ZUMA-1 …

Roth Capital’s Focus Pick: Global Blood Therapeutics Inc (GBT)

Global Blood Therapeutics Inc (NASDAQ:GBT) shares rose about 9% today after the biopharmaceutical company initiated a Phase 1 trial evaluating GBT440 in healthy volunteers under hypoxic …

Roth Capital Sees Room for Optimism Following bluebird bio Inc (BLUE) ASH Read-Out

During last week’s American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, bluebird bio Inc (NASDAQ:BLUE) provided clinical updates on …

Roth Capital Maintains Positive Stance on Global Blood Therapeutics Inc (GBT) Following Updated Clinical Results for GBT440

Roth Capital analyst Mark Breidenbach is out today with a favorable report on shares of Global Blood Therapeutics Inc (NASDAQ:GBT), after the company provided updated …

H.C. Wainwright Reiterates Buy on Pluristem Therapeutics Inc. Following FY4Q15 Financial Results

In a research report issued today, H.C.

RXi Pharmaceuticals Corp Represents An Underappreciated Innovator With Upside Potential: H.C. Wainwright

In a research report issued today, H.C.

Vical Incorporated Clinical Setback; 2 Analysts With Different Views

Vical Incorporated (NASDAQ:VICL) shares are tumbling 42.85% to $0.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts